Stocktoria
Artiva Biotherapeutics, Inc. ARTV
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-07-19
Artiva Biotherapeutics, Inc. statistics & valuation
Market cap$237.8M
P / B2.2×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | — | -26805.6% | -91.6% |
| Net margin | — | -26045.0% | -85.8% |
| FCF margin | — | -22180.9% | -151.3% |
| Return on assets | -64.0% | -31.2% | -27.3% |
| Return on equity | -76.3% | -35.0% | 17.7% |
| Current ratio | 8.61 | 15.39 | 6.53 |
| Revenue growth | -100.0% | -99.3% | — |
Source: SEC EDGAR filings · CIK 0001817241 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.